Grifols Group enters into agreement with Canadian Plasma Resources to secure plasma supply in Canada

Barcelona, Spain, June 8, 2023 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed an agreement with Canadian Plasma Resources (CPR), a Canadian plasma collector licensed by Health Canada, under which Grifols Group has the right to obtain plasma donated in CPR centers. Grifols Group has the intention to acquire CPR centers by the end of 2025.

Separate from its CPR agreement, Grifols Group also plans to open more plasma donation centers in Canada, expanding on its first, acquired in Winnipeg, Manitoba, in early 2022, and a second currently under development in Edmonton, Alberta. It expects to open as many as five additional centers in the country and is exploring potential locations in Ontario, where Grifols Group would operate as an “agent” of Canadian Blood Services per exemption under the province’s Voluntary Blood Donations Act. Precise locations for the Ontario centers, subject to prior approval by Canadian Blood Services, also depend on criteria such as population density, local talent pool and transport links. The Alberta and Ontario centers are expected to be operational in 2024. There are no current plans for locations in British Columbia.

The plasma Grifols Group collects in Canada will support the company’s long-term collaboration agreement with Canadian Blood Services, announced in September 2022, to increase Canada’s self-sufficiency in immunoglobulin (Ig) medicines through an all-Canadian supply chain. Grifols Group is working with Canadian Blood Services to steadily increase sourcing of the Canadian plasma necessary so that volumes eventually reach the agreed-to 600,000 liters to manufacture 2.4 million grams of Ig treatments annually by 2026. Production is exclusively for Canadian Blood Services and Canadian patients.

“Grifols Group is moving full speed ahead on its commitment to Canadian Blood Services, helping Canada achieve self-sufficiency for the patients there who depend on lifesaving plasma therapies,“ said Raimon Grifols, Grifols Chief Corporate Officer. “We’re ensuring that all available Canadian plasma output that we obtain remains in Canada and is manufactured into medicines in Canada to support patients in Canada.”

Grifols’ latest moves deepen its more than three-decade commitment to Canada and its patients who rely on the company’s products. In 2020, Grifols Group invested more than USD 400 million in its Montreal plasma manufacturing site, which includes a fractionation plant with a capacity of 1.5 million liters and two purification plants. This facility, which will produce Ig for Canadian Blood Services, represents Canada’s first and only large-scale plasma fractionation complex.

All Grifols Group operations in Canada will meet the regulatory and licensing requirements of Health Canada.